Title X Freeze Threatens Reproductive Health Care Access
The Trump Administration's move to withhold millions of dollars allocated for family planning services is affecting reproductive health care access in more than 20 states—including some that have made efforts to protect reproductive rights.
Enacted in 1970, Title X is the nation's sole federally funded family planning program. The program doesn't fund abortion services, but it does allocate more than $200 million annually for clinics that provide other forms of health care—including birth control, cancer screenings, and STI testing—for people from low-income households. Last week, the U.S. Department of Health and Human Services (HHS) said it is withholding funds from 16 organizations in the Title X program 'pending an evaluation of possible violations' of federal civil rights laws and President Donald Trump's Executive Order that said undocumented immigrants are barred 'from obtaining most taxpayer-funded benefits.' Affected organizations received notices from HHS that their funds would be temporarily withheld while they respond to the federal government's inquiry regarding compliance with their grant terms. Reproductive health providers have called the freeze "politically motivated.'
Read More: Trump Administration Freezes Critical Title X Funding for 16 Organizations
The government's action is threatening roughly $65.8 million in Title X funds, according to estimates by the National Family Planning and Reproductive Health Association (NFPRHA), a membership organization for family planning providers. The association estimates that about 846,000 patients could be affected by the freeze.
According to NFPRHA, clinics in 23 states have had at least some of their Title X funding frozen: Alaska, California, Connecticut, Hawaii, Idaho, Indiana, Kentucky, Maine, Minnesota, Mississippi, Missouri, Montana, New Hampshire, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and West Virginia. Seven of those states—California, Hawaii, Maine, Mississippi, Missouri, Montana, and Utah—aren't receiving any Title X dollars at all right now.
Fourteen of the 16 affected organizations are NFPRHA members. Clare Coleman, president and chief executive officer of NFPRHA, says the association has heard concerns from some of them about whether they'll be able to continue providing family planning services or even stay open if the freeze continues. 'They're going to do everything they can to stay open, to subsidize services, to keep a breadth of services, but there's a limit to what people can bear,' Coleman says.
Some of the affected organizations are based in 11 states where lawmakers have already restricted reproductive health care—Mississippi, for instance, has a near-total ban on abortion, and Utah has prohibited abortion after 18 weeks of pregnancy.
'This Title X money … is life-saving for the folks who are living in these states, and now there may be no place for them to turn inside their own state lines,' Coleman says. 'Then you start thinking about are people going to have to start crossing state lines to get birth control the way they do for abortion?'
States that have made efforts to protect reproductive rights are not immune to the Title X funding freeze. California, Hawaii, and Maine, for instance, are all Democratic-led states that have passed various laws to protect abortion rights.
'Even though California stands strongly in the protection of access to abortion and it's in our constitution, there are other ways to undermine our ability to have reproductive health,' says Democratic Rep. Judy Chu of California, who, along with 161 other House Democrats, signed a letter sent to HHS Secretary Robert F. Kennedy Jr. on April 3, urging the department to reinstate all Title X funds. 'Title X funding is essential for the many, many preventive elements of reproductive health.'
Democratic Rep. Jill Tokuda of Hawaii, who also signed the letter sent to Kennedy last week, says the freeze is 'devastating' to many communities.
'We are an island state,' Tokuda says. 'For many of our people, transportation is a barrier, income can be a barrier.' She adds that even before the freeze, Title X funding wasn't enough to ensure access for all. She says one island doesn't have any Title X-funded health center at all. Now, she's hearing from clinics that they're 'scrambling to try to keep doors open.'
'Sometimes people assume that if we have broad protections for reproductive freedoms in our state, that we are fine,' Tokuda says. '[But] they're taking away health care from our people.'
Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky (PPGNHAIK), which serves those four states as well as Idaho and western Washington, was one of nine Planned Parenthood affiliates that received a notice from HHS that its Title X funding was being withheld. Its CEO, Rebecca Gibron, says that about $150,000 is no longer being allocated to its clinics in Hawaii, and a little over $1 million is being withheld from the affiliate's clinics in Alaska. She says PPGNHAIK serves the majority of Title X patients in those states: in Alaska, Planned Parenthood clinics see nearly 3,000 Title X patients a year, and in Hawaii, they see just under 1,000.
'There is no discernible pattern here around whether the Trump Administration is choosing red states or blue states—they're attacking Planned Parenthood, and more importantly, they're attacking the patients who rely on this Title X program,' Gibron says.
In 2019, during Trump's first term, his Administration prohibited organizations or providers that receive Title X funding from providing abortion referrals. The restriction—often referred to as the 'domestic gag rule'—prompted many organizations, including Planned Parenthood, to withdraw from the Title X program. The Guttmacher Institute, which researches and supports sexual and reproductive health and rights, found that the domestic gag rule, along with the COVID-19 pandemic, led to about 2.4 million fewer people receiving care through Title X in 2020 compared with 2018. Even after former President Joe Biden rescinded the domestic gag rule in 2021, Gibron says states like Alaska were still 'struggling to rebuild the safety net.'
Maine Family Planning is the sole Title X recipient in the state. With Title X dollars, the organization manages more than a dozen sites, including a mobile medical unit, and distributes funds to other health centers. Maine Family Planning serves between 28,000 and 30,000 patients through the Title X program across the organization's network of providers, says president and CEO George Hill.
HHS is withholding $1.925 million from the organization at the moment, which is about 20% of its operating budget, according to Hill. Maine Family Planning is responding to the government's inquiry, and in the interim, is relying on private funds to maintain operations, Hill says. He adds that the Maine state legislature is considering a bill that would allocate funding for family planning services, which he is hoping would help mitigate the loss of Title X dollars. But if that is unsuccessful, Hill says the organization will have to consider closing some of its clinics, including in rural communities that 'quite literally are the sole source of health care for many people in those areas.'
'I think this is the tip of the iceberg,' Hill says. 'I think the reaction is going to be exactly what happened after [Dobbs v. Jackson Women's Health Organization]: You're going to have some states that are in better positions to support their sexual and reproductive networks, and some states where you're going to have sexual and reproductive health care deserts.'
In Missouri, voters made history in November when they passed a ballot measure to enshrine the right to abortion until fetal viability in the state constitution (with exceptions after that if the pregnant person's life or health is at risk). It marked the first time that a citizen-initiated ballot measure repealed a near-total abortion ban since the U.S. Supreme Court overturned Roe v. Wade. Despite that, anti-abortion lawmakers have been trying to block access to abortion care in the state.
The state's sole Title X recipient, Missouri Family Health Council, is one of the 16 organizations that had their funding frozen by HHS. The council's executive director, Michelle Trupiano, says that a total of $8.5 million is being withheld from the organization, which Missouri Family Health Council would have distributed to clinics both in Missouri and Oklahoma. (Some organizations receiving Title X money distribute funds to clinics in multiple states.)
'Without this funding, if it goes much longer, we are at a critical point where we see health centers that are going to be closing their doors,' Trupiano says. She says her team has been communicating with health centers about contingency plans, but that 'business as usual' will likely last only a few weeks. Even if centers remain open, some of them won't be able to offer a sliding fee scale anymore, which will make services unaffordable for many patients who now visit clinics through the Title X program, Trupiano says.
'The health centers are already and they have for years been working on what we would call a shoestring budget,' Trupiano says. 'Any freeze in funding, any cuts to funding, is detrimental to their ability to stay open because they were already working at a deficit.' She says that, on top of the Title X freeze, many health centers are experiencing other public health funding cuts.
Unlike providers in other states, Trupiano doesn't anticipate that Missouri lawmakers will help make up for the Title X funding freeze; she says the state legislature generally hasn't been supportive of reproductive health care. 'There's a disconnect from what voters want, what people want, what they're consistently saying they want, and yet what policymakers are actually prioritizing,' Trupiano says.
The day after the Title X funding freeze went into effect, Planned Parenthood of Michigan (PPMI) announced that it was permanently closing three of its health centers in the state, effective April 30, and that it would be consolidating two health centers in Ann Arbor by May 5.
Paula Thornton Greear, president and CEO of PPMI, says the affiliate hasn't received a notice from HHS that its Title X funding would be withheld, but that the organization expects that it will arrive 'on our doorstep very shortly.' She says the prospect of the Title X freeze, in addition to other threats to health care, such as the possibility of states barring Planned Parenthood from the Medicaid program, forced PPMI to 'make these heart-wrenching decisions in order to ensure the long-term sustainability' of the organization.
'We've been contingency planning for months in anticipation of the Trump Administration coming and really taking what they did in 2019 to a whole new level,' Thornton Greear says. 'The complexity and the layered approach of this is devastating, and that's why we were forced to make the decision.'
PPMI said it plans to expand its virtual health services over the next few months, including by offering telehealth seven days a week to provide services like birth control, medication abortion, and gender-affirming care. In 2022, voters in Michigan passed a ballot measure to enshrine the right to abortion in the state constitution.
'In Michigan, the constitutional protections that we have for reproductive freedom—that's absolutely crucial. It ensures that we can keep providing the full spectrum of reproductive health care without state level interference,' Thornton Greear says. 'That's a lifeline that many of our colleagues in other states simply did not have.'
'However, here's the reality: these constitutional protections don't shield us from federal funding cuts,' she says. 'While we can legally provide abortion care in Michigan, the ability to maintain affordable access across our services still depends heavily on programs like Title X, like Medicaid. The ballot measure protects the right, but not necessarily the accessibility or the affordability.'
Many reproductive rights experts believe this Title X funding freeze is just the beginning of further federal cuts to family planning and reproductive health services. 'Everybody needs to be doing contingency planning,' Coleman says. 'Everybody now needs to be concerned that they may lose their Title X, whether it's for a time or whether it's for all time.'
And experts fear that additional cuts will result in people who need health care services the most being left out of the system.
'Health care disparities in this country are not new, but right now, we're facing an Administration that wants to take a widening gap of health care disparities and turn it into a chasm that can never close,' Thornton Greear says. 'For every dollar that is stripped away, we're going to lose people.'
Contact us at letters@time.com.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
an hour ago
- Forbes
AstraZeneca's CFO On The Company's Bet To Increase Its U.S. Business
President Donald Trump has not shied away from making demands of private industry, and he formalized one of them last week. On Thursday, he sent letters to 17 pharmaceutical companies, demanding that they lower prices for U.S. customers. The letters are in keeping with the 'Most-Favored Nation' executive order Trump signed in May, aiming to align U.S. drug prices with those for other developed countries. Responses have varied. Pfizer said it's working with the Trump Administration and Congress on solutions to increase access and affordability for Americans. The trade group Pharmaceutical Research and Manufacturers of America said that importing foreign drug price controls to the United States would 'undermine American leadership,' and suggested that policymakers instead rein in the 'health care middlemen' who add complexity to the system and further drive up prices. But before these letters were sent, one of the world's largest drugmakers had already announced its intent to lower U.S. prices. AstraZeneca, the British pharmaceutical giant that makes key treatment drugs for cancer, cardiovascular health and respiratory conditions, had already announced serious efforts to reduce U.S. prices. On the company's Q2 earnings call last Tuesday, CEO Pascal Soriot said that they believe a 'rebalancing of pricing around the world is necessary. The U.S. can no longer pay for the R&D of the world.' In an interview after the earnings report, CFO Aradhana Sarin told me that while this is a complicated situation, AstraZeneca planned on increasing and improving its U.S. business, even before Trump's second term was guaranteed. Last year, the company announced a goal to deliver $80 billion in annual revenue by 2030—up from $45.8 billion in 2023—with half of that coming from the U.S. And that's through new business, not increasing prices on Americans. Drug prices here, she said, are determined through a complicated system. 'If you're familiar with the US healthcare system, there's a lot of money that goes in between,' Sarin told me. 'People think of pharma companies benefiting from that, but that's often not the case.' Today's edition of Forbes CFO focuses on Sarin, her nontraditional path to becoming CFO of a major pharmaceutical company, and how she's leading the company on a strategy intended to both encourage business growth and increase ties to the U.S. This is the published version of Forbes' CFO newsletter, which offers the latest news for chief finance officers and other leaders focused on the budget. Sign up here to get it delivered to your inbox every Tuesday. A NONTRADITIONAL PATH Most CFOs have deep backgrounds in business and finance, which Sarin has. She earned an MBA from Stanford University and has worked in the investment banking space for more than two decades. She moved to working in corporate strategy for Alexion Pharmaceuticals in 2017, becoming its CFO in 2019, and became AstraZeneca's CFO when it acquired Alexion in 2021. But prior to all of that, Sarin had been a medical doctor in India and Tanzania. 'Learning medicine was a lot of fun, but practicing was not the same,' she said. 'And I felt like I could do much more going broader into business.' Hands-on experience in how the medical field works has given Sarin important insight into the science behind drug development. AstraZeneca spends about $14 billion on R&D annually, she said, and the drug development cycle is long. It's not unusual for a drug to take eight to 10 years to get through the regulatory pipeline. And the entire process is fraught with risks. It's hard to know which potential products will end up being successful. AstraZeneca CFO Aradhana Sarin. AstraZeneca 'The background helps in making the judgment and the risk assessment of where you want to put that type of R&D money behind the highest probability of success assets, knowing that you are still taking risks,' she said. Knowing the pharmaceutical market from the patient care side also helps to make business decisions, Sarin said. Understanding the unmet need a drug can solve—as well as who the target patient is, how they will get the drug and how they will pay for it—informs the corporate process. 'It makes a huge difference when you think of it from the lens of a clinician and say, 'Okay, as a physician, how would you treat this patient?'' she said. INVESTMENT AND OPPORTUNITY AstraZeneca CEO Pascal Soriot announces the company's planned $50 billion investment in the U.S. at an event in Washington, D.C. last month, as Virginia Gov. Glenn Youngkin and AstraZeneca executive vice president for global operations Pam Cheng look on. Al Drago © 2025 Bloomberg Finance LP AstraZeneca's big U.S. push looks like something that many international companies are pursuing today, both to escape new impending Trump tariffs and to appease the president. Sarin said that isn't the case for AstraZeneca, which announced its plan to expand its U.S. business last spring. Last month, AstraZeneca made another announcement deepening its commitment to the U.S. It will invest $50 billion in U.S. facilities for R&D and manufacturing by 2030. But, Sarin said, this announcement had little to do with Trump. 'For us, it was a business decision,' she said. 'We didn't rush to make any announcements as some of our peers did several months back.' The most significant portion of the investment, a manufacturing facility in Virginia that will make drug substances for its metabolic and weight management portfolio, will represent AstraZeneca's largest single manufacturing investment in the world. Sarin said that the deal materialized quickly. AstraZeneca had a clear vision for what they wanted to build and was looking at sites in several states. But Virginia had its eyes on the prize. Sarin said there were just 33 days from their first conversation with the state to the facility announcement. AstraZeneca tends to move quickly in negotiations, she said, but governments often do not. However, Virginia Gov. Glenn Youngkin was an investment banker before he came to government, and Sarin noted the state's current economic development office is structured more like one in the private sector, with analysts and economists looking for the best opportunities and seizing on them. 'Bringing what you see often on the private side and on the business side—that type of working-style agility, get-it-done type of agenda and objectives to do this—I think made a big difference.' The exact location and timeline for this facility construction have not yet been announced. The other areas where AstraZeneca plans to invest include expanding its R&D facility in Gaithersburg, Maryland; an R&D center in Cambridge, Massachusetts; manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; and expanding manufacturing facilities in Mount Vernon, Indiana and Coppell, Texas. EXPANSION PROGRESS A person walks by the sign at the AstraZeneca facility in Gaithersburg, Maryland. Graeme Sloan © 2024 Bloomberg Finance LP AstraZeneca is making progress with its goals to expand its business, both overall and in the U.S. In its earnings last week representing the first half of 2025, the company reported more than $28 billion in revenues, an increase of 11% above 2024. The U.S. represents about 43% of that total. To focus more on the U.S., Sarin said AstraZeneca had already decided to shift more of its operations here. 'We have been deliberate on research. Not just labs—which we do have plenty of labs as well, but also clinical trials,' Sarin said. 'There's been a big investment to make sure.' AstraZeneca currently strives to do at least 10%, if not more, of all clinical trials in the U.S., she said. It represents a new tack; more of the trials used to take place in Europe. However, increased reach into the U.S. isn't the only place where AstraZeneca is seeing growth. In its results last week, the company saw expansion across the board. Cancer drugs represented 44% of its earnings. Respiratory and immunology drugs saw 15% growth in the quarter, and Sarin remarked that many of those have only been on the market a few years, so there is a lot of runway for more growth. There's more in AstraZeneca's R&D pipeline, Sarin said, but there's also bound to be growth as some of the company's newer drugs are found to be effective in treating other conditions. STRATEGIC PARTNERSHIP The degree of expertise that Sarin has in the business of the company she works at is rare, but she said that any CFO can become a true strategic partner. It takes time to devote to learning about the industry and its ins and outs, and CFOs now have a powerful opportunity to use their expertise—both about finances and industry—to shape what a company does going forward. Sarin says she sees herself as a transformational leader, which all CFOs should be. CFOs will remain central to company strategy, she said, because they control the money—which touches everything the company does. No amount of technology, AI platform or change to the structure of business can shake the CFO's importance. 'The CFO would be very much a transformation driver because businesses will still be about money or how money flows,' she said. COMINGS + GOINGS Packaging provider Sealed Air named Kristen Actis-Grande as its new chief financial officer, effective August 25. Actis-Grande joins from MSC Industrial Supply Co., where she worked as executive vice president and chief financial officer. named as its new chief financial officer, effective August 25. Actis-Grande joins from MSC Industrial Supply Co., where she worked as executive vice president and chief financial officer. Shipping solutions company Pitney Bowes appointed Paul Evans as EVP, chief financial officer and treasurer, effective July 29. Evans most recently worked as chief operating officer at America's Auto Auction Group, and is replacing Robert Gold. appointed as EVP, chief financial officer and treasurer, effective July 29. Evans most recently worked as chief operating officer at America's Auto Auction Group, and is replacing Robert Gold. Nuclear technology firm BWX Technologies promoted Mike Fitzgerald to its chief financial officer role. Fitzgerald, who had been interim CFO since May 12, was previously the vice president for finance and chief accounting officer at BWXT. STRATEGIES + ADVICE ChatGPT can give you prime advice on how to improve your strategy, but you need to use it the right way: Consult it like a cofounder, not a search engine. A highly motivated workforce can improve your productivity, but it needs the right incentives and recognition. Here are some tips to determine the best ways to motivate your team to perform its best. QUIZ Last week, a second company achieved a valuation of more than $4 trillion, though its current value is below that mark. Which company was it? A. Apple B. Amazon C. Google D. Microsoft See if you got the right answer here.


American Press
an hour ago
- American Press
Rollins extends sugary drinks ban to six more states — including Louisiana
U.S. Secretary of Agriculture Brooke Rollins approved six waivers to exclude sodas and energy drinks from federal nutrition programs on Monday. Rollins signed waivers exempting soda and energy drinks from being included in the Supplemental Nutrition Assistance Programs in Colorado, Florida, Louisiana, Oklahoma, Texas and West Virginia. The six states join Arkansas, Idaho, Iowa, Indiana, Utah and Nebraska in restricting sodas and energy drinks from SNAP. 'Since my confirmation, our department has encouraged states to think differently and creatively about how to solve the many health issues facing Americans,' Rollins said. 'One way is by not allowing taxpayer-funded benefits to be used to purchase unhealthy items like soda, candy and other junk food.' Critics of the new push to ban soda and energy drinks under SNAP say it unfairly targets lower-income families, limits consumer choice and won't result in better health outcomes. Colorado Gov. Jared Polis is the first Democrat governor to request a waiver of sugary drinks from the states SNAP program. 'This is not red or blue, Republican or Democrat. We are discussing and working with every state. So (I am) really excited to continue to work with Gov. Polis,' Rollins said. Secretary of Health and Human Services Robert F. Kennedy Jr., Food and Drug Administration Commissioner Marty Makary, Iowa Gov. Kim Reynolds and West Virginia Gov. Patrick Morrisey joined Rollins for the announcement. Morrisey praised his state's inclusion as part of the SNAP waiver program. He said the lack of access to healthy foods in West Virginia contributes to the prevalence of chronic disease in residents. 'I'm happy now that West Virginia taxpayers are not going to be subsidizing soda and these sugary drinks, things that have no nutritional value and are directly linked to obesity, diabetes, and a lot of other terrible health care outcomes,' Morrisey said. HHS Secretary Kennedy agreed with Morrisey. He said the inclusion of soda and energy drinks in SNAP increases the cost to medicaid and medicare programs due to increased chronic disease. 'U.S. taxpayers should not be paying to feed kids foods – the poorest kids in our country – with foods that are the gift of diabetes. And my agency ends up through Medicaid and Medicare paying for those injuries,' Kennedy said. Kennedy also gave an update on the dietary guidelines for Americans that he is working alongside Rollins to complete. He said the guidelines will be complete in late September, 'three months ahead of schedule.' 'They will drive changes in the school lunch program, in prison lunches and military food, and they will begin to change America almost immediately,' Kennedy said. Not everyone agrees. 'Make no mistake, this waiver won't make an ounce of difference on health,' the trade organization American Beverage said when a waiver was being discussed in Ohio. 'Obesity has skyrocketed in the last two decades while beverage calories per serving have dropped by 42% – thanks to our industry's efforts to empower Americans with more choice and information. In fact, 60% of beverages Americans buy today have zero sugar due to our innovation.' The U.S. government spent $112.8 billion on SNAP in 2023, covering 100% of the cost of food benefits and 50% of states' administrative costs.


Washington Post
2 hours ago
- Washington Post
Trump administration wants to end abortion coverage through Veterans Affairs
President Donald Trump's administration is calling to remove abortion coverage from the list of medical benefits for veterans and their families, saying it's not needed. The Department of Veterans Affairs posted the proposed rule change on Monday and opened a public comment period on it that runs through Sept. 3. The department said in its proposal that it wants to ensure it 'provides only needed medical services to our nation's heroes and their families.'